Hematopoietic chimerism as a predictive marker for the relapse of acute leukemia after
allogeneic BMT was evaluated in a prospective study. Monthly assays of hematopoietic …

Although generally not applied as first-line treatment of multiple myeloma, allogeneic
hematopoietic cell transplantation (allo-SCT) can still be chosen as ultimate escalation …

Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA)
have potential pitfalls as diagnostic means for the detection of minimal residual disease after …

Allogeneic hematopoietic cell transplantation (HCT) is the treatment of choice for high-risk
myeloid and lymphoid leukemias. Relapse after allogeneic HCT is associated with a dismal …

The last decade has witnessed a multistep evolution in the understanding of the natural
history, clinical manifestations, and some of the molecular mechanisms that underlie the …

Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder of early
childhood. In all, 21 patients with JMML who received donor leukocyte infusion (DLI) after …

Single-nucleotide polymorphisms (SNPs) have the potential to be particularly useful as
markers for monitoring of chimerism after stem cell transplantation (SCT) because they can …

Donor lymphocyte infusion (DLI) is an effective method to establish full donor chimerism or
to prevent and treat relapse after allogeneic haematopoietic cell transplantation (allo‐HCT) …

We retrospectively analyzed the prognostic significance of mixed chimerism and associated
clinical parameters in 80 patients following unmanipulated allogenic stem cell …

Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT)
using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity …